FR0013286259

Podrobnosti o dividendah

Razumevanje dividendnih izplačil od Theranexus

Dividende od Theranexus so del dobička podjetja, ki se izplača delničarjem. So ključen kazalec finančnega zdravja podjetja in privlačnosti za vlagatelje. Dividende vlagateljem nudijo stalni vir dohodka, poleg dobičkov, ki se lahko pridobijo s prodajo delnice po višji ceni od nakupne.

Primerjava iz leta v leto

Proučevanje dividendnih izplačil od Theranexus čez leta lahko izpostavi donosnost in stabilnost podjetja. Konstantna ali naraščajoča dividendna izplačila lahko kažejo na finančno zdravo podjetje s predvidljivimi dobički, medtem ko lahko nihanje ali znižanja dividend nakazujejo na obstoječe finančne ali operativne izzive.

Vplivi na investicije

Izplačila dividend od Theranexus so ključni dejavnik za vlagatelje, ki so usmerjeni na dohodek. Močno izplačilo dividend lahko poveča privlačnost delnice in zagotovi redni dohodek poleg morebitnih kapitalskih dobičkov. Lahko tudi pokaže zaupanje podjetja v svoje prihodnje dobičke in je tako pomemben dejavnik pri odločitvah o naložbah.

Interpretacija nihanj dividend

Spremembe v dividendah od Theranexus lahko nastopijo zaradi sprememb v dobičkih podjetja, finančni politiki ali strategijah reinvestiranja. Povečanje dividend pogosto signalizira finančno stabilnost, medtem ko znižanje lahko nakazuje na potrebo po ohranjanju denarnih sredstev ali reinvestiranju dobičkov za spodbujanje rasti, pri čemer ima vsak scenarij različne posledice za vlagatelje.

Theranexus Aktienanalyse

Kaj počne Theranexus?

Theranexus SA is a French biotechnology company founded in Lyon in 2013. The company specializes in the development of drugs for the treatment of neurodegenerative diseases. It is one of the few companies specialized in the synthesis of drug candidates through the combination of molecules. The idea to create Theranexus arose from the collaboration between Mathieu Charveriat and Franck Mouthon, two experienced researchers who both worked at the CNRS laboratory at the University of Lyon. Their goal was to synthesize a new class of molecules that are more effective in the treatment of neuropsychiatric disorders such as depression, anxiety, narcolepsy, and Alzheimer's. The company specializes in two main areas: the development of novel drugs and the identification of drug candidates through the modulation of molecules that influence neuronal communication. Theranexus closely collaborates with academic partners to develop a wide range of therapeutic options for neurodegenerative diseases. The company focuses on the development of drugs that work in a unique and seamless way. Theranexus SA has a unique business model in the field of drug development. The company utilizes its innovative technology platform to combine and rearticulate molecules that can influence neuronal communication. The company aims to expand its technology platform and extend its research to other disease areas. The company operates two main activities: the development of drug candidates for the treatment of neurodegenerative diseases and the identification of new drug candidates through the modulation of molecules that influence neuronal communication. The company has recently developed a cathepsin S platform that focuses on the discovery of drugs and drug candidates for the treatment of neurodegenerative diseases. Cathepsin S is an enzyme involved in the formation of amyloid deposits that can play a role in Alzheimer's disease and other neurodegenerative diseases. Theranexus has also developed a platform for the formation of nanoparticles to enable drugs to have a longer half-life and reduce dosage. The company utilizes the platform to stabilize therapeutic molecules by modifying their chemical properties in the body. Theranexus's current products include ANX-368, a drug candidate for the treatment of narcolepsy, and THN102, a combination drug for the treatment of Parkinson's and sleep disorders. The drug candidate TNX-102 is being developed as a potential medication for the treatment of neuropathic pain. Overall, Theranexus SA aims to develop effective and innovative drugs for the treatment of neurodegenerative diseases. The company is committed to expanding its technology platform and continuing its research in other disease areas. Theranexus je eno izmed najbolj priljubljenih podjetij na Eulerpool.com.

Pogosta vprašanja o delnici Theranexus

Koliko dividende izplača Theranexus?

V zadnjih 12 mesecih je Theranexus izplačal dividendo v višini . To ustreza približni donosnosti dividend . V prihajajočih 12 mesecih bo Theranexus predvidoma izplačal dividendo v višini 0 EUR.

Kakšen je donos dividend od Theranexus?

Trenutni donos od dividend za Theranexus znaša .

Kdaj Theranexus izplača dividend?

Theranexus izplačuje četrtletno dividendo. Ta se izplačuje v mesecih .

Kako varna je dividenda od Theranexus?

Theranexus je v zadnjih 0 letih vsako leto izplačeval dividend.

Kakšna je dividenda od Theranexus?

V naslednjih 12 mesecih se pričakuje dividende v višini 0 EUR. To ustreza dividendnemu donosu 0 %.

V katerem sektorju se nahaja Theranexus?

Theranexus je razvrščen v sektor 'Zdravje'.

Wann musste ich die Aktien von Theranexus kaufen, um die vorherige Dividende zu erhalten?

Da si prejel zadnjo dividendo Theranexus z dne 19. 6. 2024 v višini 0 EUR, si moral imeti delnico v depoju pred dnevom brez pravice do dividende (Ex-Tag) 19. 6. 2024.

Kdaj je Theranexus izplačal zadnjo dividendo?

Zadnje izplačilo dividende je bilo 19. 6. 2024.

Kakšna je bila dividenda od Theranexus v letu 2023?

V letu 2023 je Theranexus 0 EUR izplačal kot dividende.

V kateri valuti Theranexus izplača dividendo?

Dividende od Theranexus se izplačujejo v EUR.

Theranexus Dividenda 2024

Theranexus Dividenda

Theranexus Donosnost dividend

Simbol

ISIN

WKN

Koliko dividende izplača Theranexus 2024?

Zgodovinske Theranexus dividende

Je Theranexus dividenda varna?